Clinical Trial: Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07925268) titled 'Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer' on Nov. 03.

Brief Summary: This is a Phase 2, open-label, single-arm study evaluating the safety and effectiveness of ifinatamab deruxtecan (I-DXd) in adult men with histologic evidence of de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). I-DXd is an investigational antibody-drug conjugate (ADC) designed to target B7-H3, a protein found at high levels on many neuroendocrine prostate cancer cells. After binding to B7-H3, I-DXd delivers an anticancer drug called deruxtecan (DXd) to tumor cells. DXd interferes with an enzy...